'Digoxin conundrum - Time for validation?'
1C.E.O. & Chief Cardiac Surgeon, National Heart Institute, 49-50 Community Centre, East of Kailash, New Delhi, 110065, India.
Abstract:
Despite no incontrovertible data, Digoxin use has been demonised. As a consequence, a lot of patients, stable on Digoxin, have been taken off it and offered alternative drugs. However, there is some light at the end of the tunnel for Digoxin, with the reporting of RATE-AF Trial at the recent European Society of Cardiology Congress. Compared to Bisoprolol, Digoxin use was associated with statistically significantly greater improvements in symptomatology and NT ProBNP levels making Digoxin a first line drug for rate control in permanent AF.
More Related Videos
14:03High-Throughput Cardiotoxicity Screening Using Mature Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Monolayers
Published on: March 24, 2023
08:11Voltage-Dependent Potassium Current Recording on H9c2 Cardiomyocytes via the Whole-Cell Patch-Clamp Technique
Published on: November 11, 2022
Related Concept Videos
Heart Failure Drugs: Inotropic Agents
Dysrhythmias V: Evaluating Dysrhythmias
Dysrhythmias VI: Management of Dysrhythmias
Dysrhythmias I: Introduction
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations
Dysrhythmias VII: Nursing Management of Dysrhythmias
